This is the authors' abstract. We don't add key points for this paper.
Half an hour after reperfusion, the kidney, transplanted to the infant from an adult brain dead standard criteria donor, became flabby and acquired blue color. Hyperacute rejection was suspected as a consequence of false negative cross match, and eculizumab was administered with the purpose to treat antibody-mediated injury, with fast and clear effect. The patient's blood was tested for donor-specific antibodies on the next day, and results were negative. We attribute graft damage to reperfusion injury and explain eculizumab's effectiveness to its ability to prevent progression of reperfusion injury.
Answers are grounded in this paper and cite their sources.
No takes yet. Share an insight, caveat, or question.
Каабак et al. (2013) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: